Janet A. Englund
Seattle Children's Research Institute
423 Papers
3.1K Citations
Janet A. Englund is an academic researcher from Seattle Children's Research Institute. The author has contributed to research in topics: Medicine & Vaccination. The author has an hindex of 80, co-authored 360 publications. Previous affiliations of Janet A. Englund include Vanderbilt University & University of Texas MD Anderson Cancer Center.
Chat about Author
Papers
Duration of immunity against pertussis after natural infection or vaccination.
TL;DR: A review of the published data on duration of immunity reveals estimates that infection-acquired immunity against pertussis disease wanes after 4–20 years and protective immunity after vaccination wanesAfter 4–12 years.
699
Valganciclovir for Symptomatic Congenital Cytomegalovirus Disease
David W. Kimberlin,Penelope Jester,Pablo J. Sánchez,Amina Ahmed,Ravit Arav-Boger,Marian G. Michaels,Negar Ashouri,Janet A. Englund,Benjamin Estrada,Richard F. Jacobs,Jose R. Romero,Sunil K. Sood,M. S. Whitworth,Mark J. Abzug,Mary T. Caserta,Sandra L. Fowler,Jorge Lujan-Zilbermann,Gregory A. Storch,Roberta L. DeBiasi,Jin Young Han,April Palmer,Leonard B. Weiner,Joseph A. Bocchini,Penelope H. Dennehy,Adam Finn,Paul D. Griffiths,Suzanne Luck,Kathleen Gutierrez,Natasha B. Halasa,James Homans,Andi L. Shane,Mike Sharland,Kari A. Simonsen,John A. Vanchiere,Charles R. Woods,Diane L. Sabo,Inmaculada Aban,Hui-Chien Kuo,Scott H. James,Mark N. Prichard,Jill Griffin,Dusty Giles,Edward P. Acosta,Richard J. Whitley +43 more
TL;DR: Treating symptomatic congenital CMV disease with valganciclovir for 6 months, as compared with 6 weeks, did not improve hearing in the short term but appeared to improve hearing and developmental outcomes modestly in the longer term.
Seasonal Influenza in Adults and Children—Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management: Clinical Practice Guidelines of the Infectious Diseases Society of America
Scott A. Harper,John S. Bradley,Janet A. Englund,Thomas M. File,Stefan Gravenstein,Frederick G. Hayden,Allison McGeer,Kathleen M. Neuzil,Kathleen M. Neuzil,Andrew T. Pavia,Michael L. Tapper,Michael L. Tapper,Timothy M. Uyeki,Richard K. Zimmerman +13 more
TL;DR: These guidelines are intended for use by physicians in all medical specialties with direct patient care, because influenza virus infection is common in communities during influenza season and may be encountered by practitioners caring for a wide variety of patients.
Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa
Timothy M. Uyeki,Henry H. Bernstein,John S. Bradley,John S. Bradley,Janet A. Englund,Thomas M. File,Alicia M. Fry,Stefan Gravenstein,Frederick G Hayden,Scott A. Harper,Jon Mark Hirshon,Michael G. Ison,B Lynn Johnston,Shandra L Knight,Allison McGeer,Laura E. Riley,Cameron R. Wolfe,Paul E. Alexander,Paul E. Alexander,Andrew T. Pavia +19 more
TL;DR: These clinical practice guidelines are an update of the guidelines published by the Infectious Diseases Society of America in 2009 and address new information regarding diagnostic testing, treatment and chemoprophylaxis with antiviral medications, and issues related to institutional outbreak management for seasonal influenza.
Safety and Immunogenicity of Tetanus Diphtheria and Acellular Pertussis (Tdap) Immunization During Pregnancy in Mothers and Infants: A Randomized Clinical Trial
Flor M. Munoz,Nanette Bond,Maurizio Maccato,Phillip Pinell,Hunter Hammill,Geeta K. Swamy,Emmanuel B. Walter,Lisa A. Jackson,Janet A. Englund,Morven S. Edwards,C. Mary Healy,Carey R. Petrie,Jennifer Ferreira,Johannes B. Goll,Carol J. Baker +14 more
TL;DR: This preliminary assessment did not find an increased risk of adverse events among women who received Tdap vaccine during pregnancy or their infants, and further research is needed to provide definitive evidence of the safety and efficacy of TdAP immunization during pregnancy.
474